VALUENCE
Valuence Japan Inc. (Tokyo; Susumu Muguruma, representative director and president), a member of the Valuence Group (TOKYO:9270), announced on July 1, the launch of the official version of its winning bid market price chart, available by subscription. The official version of the service has been upgraded and comes with new, useful features. Star Buyers Auction is a luxury brand goods auction service operated by Valuence Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210716005104/en/
New Features and Upgrades Reflect Partner Input
The Valuence Japan-operated Star Buyers Auction is a pre-owned luxury branded goods B2B auction and the main sales channel of the Valuence Group. Since the launch of Star Buyers Auction, the service has continued to grow in scale, adding new categories and offering new services, including online global auctions. In February 2021, Valuence Japan introduced a beta version of a market price chart subscription service for use by partners around the world. This service displays global market prices (actual winning auction bids) for a variety of goods. The company received abundant and valuable feedback from its partners regarding bidding and consignment sales, at the same time attracting an increasing number of new subscribers.
Valuence Japan added new functions to the Star Buyers Auction market price chart subscription service, incorporating feedback from partners. The company released the official upgraded version of the service on July 1. At the same time, the company will continue to look at upgrading the service based on feedback, striving to create a global reuse platform serving as an indispensable part of the purchasing and selling markets.
Official Version and Upgrades
The official version of the market price chart service now allows users to enter multiple search terms, including brand and model names. This powerful upgrade reduces time spent in search for specific products. Users may also conduct searches by transaction date range, providing a narrower view of the vast amount of transaction data available. The search results screen now displays accessories, prices, and transaction dates in either ascending or descending order. Here, users will be able to sort through information, including accessories, price ranges, and other data for multiple products. Search results draw on the more than 25,000 items sold every auction, demonstrating the vast amount of valuable market data accumulated by Star Buyers Auction.
Valuence Japan is confident that the upgraded version of this service will deliver the type of market price information needed and used by the B2B auction partners.
Star Buyers Auction Overview
A luxury brand goods auction for reuse business dealers, launched in April 2013. In April 2020, auctions were migrated to a fully online format, listing a constantly stable stream of luxury items both in quantity and quality. Listings primarily focus on watches, bags, and brand jewelry procured by the Valuence Group. Auctions are held twice monthly. Market price chart subscription service is also available for 11,000 yen per month.
Official Site: https://biz.starbuyers-global-auction.com/en/
Youtube: https://youtu.be/efUtXrO9JkE
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005104/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom